Keyword: Regeneron Pharmaceuticals
The phase 1b study tested KSI-301 in age-related macular degeneration, diabetic macular edema or macular edema from retinal vein occlusion.
Sanofi and Regeneron’s IL-33 antibody performed numerically worse than Dupixent and showed little promise in combination with the approved drug.
The revision of the original deal ties Aslan to milestones including a $30 million payment when ASLAN004 enters phase 3.
Kodiak Sciences has filed to raise up to $100 million in its IPO to support the development of its anti-VEGF drug for eye diseases.
The committee made the call after assessing the risk-benefit profile of the osteoarthritis regimens based on data generated to date.
If the pair finds potential treatments in the discovery deal, they will ink a new collaboration to advance them.
Aya Jakobovits is retaining her seat on the board and will serve as a strategic adviser but is no longer president and CEO of the firm she founded.
Roche's antibody RG7716 in diabetic macular edema could be a threat to current blockbuster VEGF drugs used for the disease.
AstraZeneca and Amgen’s tezepelumab missed the primary endpoint in a phase 2a atopic dermatitis trial, raising doubts about its prospects.
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.